LON:NIOX - Niox Group PLC
Executive Summary
Niox Group PLC (LON:NIOX) is a UK-listed medical device company specialising in point-of-care and clinical FeNO (fractional exhaled nitric oxide) testing, principally used in the diagnosis and management of asthma. The group markets its NIOX branded devices and consumables globally and is recognised as one of the established players in the FeNO segment, with its products used in respiratory clinics, hospitals and primary care settings.
The investment case rests on a named 10-year sensor supply agreement, ongoing NIOX PRO regulatory progress and a confirmed takeover approach from Keensight, reinforced by a GBP 12.5 million tender offer at 80p per share, all of which provide near-term cash certainty to shareholders. The primary risk is the filing-disclosed concentration of sales in FeNO asthma testing products, which leaves the group exposed to reimbursement and regulatory headwinds in any single market. The 2026 Annual General Meeting on 21 May 2026, which will consider the final 2025 dividend, is the most material scheduled event on the near-term calendar.
BUY. Conviction Score: 66/100. The view would be downgraded if the Keensight approach were withdrawn without an alternative bid, if NIOX PRO regulatory progress were to stall materially, or if a major reimbursement cut in the United States or a key European market were to compress FeNO test volumes into the 2027 financial year.
Bottom line - BUY at 66/100.
Thesis break: Withdrawal of the Keensight takeover approach without an alternative bid, combined with a US reimbursement cut for FeNO testing that drives consumables revenue growth below 5% for two consecutive half-years.
Business Model
Niox generates revenue through the sale of its NIOX VERO and related FeNO measurement devices, which are placed with clinical customers, and the recurring sale of single-use consumables required to operate each device. The consumables stream is the higher-quality component of the mix because every patient test requires a fresh sensor and breathing handle, which creates a razor-and-blade dynamic with predictable, volume-linked revenue. Device placements broaden the installed base, which in turn expands the consumable annuity.
The customer base spans hospital respiratory departments, specialist allergy and asthma clinics, primary care practitioners and, in some markets, clinical research organisations. Pricing is denominated predominantly in US dollars and euros, reflecting the geographic skew of the installed base, while the group reports in pounds sterling. Reported gross margins of 71% at the half-year stage underline the consumables-heavy mix, and adjusted EBITDA growth of 21% to GBP 16.7 million, up from GBP 13.8 million, indicates operating leverage as the installed base expands.
The competitive moat is built on the regulatory clearances and clinical evidence accumulated around the NIOX platform, which make it operationally cumbersome for clinicians to switch suppliers once embedded in workflow. Concentration in FeNO is, however, both the moat and the principal vulnerability: a single technology platform addresses a single clinical use case, and any change in guideline support or reimbursement can flow through quickly to test volumes.
Financial Snapshot
Recent Catalysts
[17 April 2026] - Niox Group disclosed that insider Jonathan Emms sold 325,273 ordinary shares, a routine insider transaction reported in the same release window as quarterly earnings of GBX 4.03 per share. Source: Daily Political.
[18 April 2026] - Niox Group shares were reported trading down 1.1% in the session following the latest earnings update, with the company having last posted quarterly results on 24 March 2026. Source: Markets Daily.
[24 March 2026] - Niox Group issued quarterly earnings results, reporting earnings per share of GBX 4.03 for the quarter, alongside a disclosed net margin of 14.37% and a positive return on equity. Source: Markets Daily (citing Digital Look Earnings).
[March 2026] - Niox Group reported 17% revenue growth and confirmed that 2025 results exceeded management expectations, reinforcing the case for the GBP 12.5 million tender at 80p and the cash on balance sheet. Source: Investing.com.
[21 May 2026] - Niox Group is scheduled to hold its 2026 Annual General Meeting, at which shareholders will consider the 2025 final dividend, with the timetable previously set out by the company. Source: Niox Group RNS announcement (via Investegate).
Thesis Evaluation
Bull Case (33% weight)
FeNO test volumes continue to compound on the back of asthma and respiratory guideline support, the 10-year sensor supply agreement underpins multi-year revenue visibility, and either NIOX PRO clearance or a successful Keensight transaction crystallises value well above the current 66.8p. The GBP 12.5 million tender at 80p provides a near-term floor, while a bid-led re-rating or a regulatory step-up can deliver meaningful upside. 120p over a 12-month horizon.
Base Case (51% weight)
Revenue continues to grow at a high-teens pace in line with the 17% reported in the most recent update, gross margins hold near 71% and adjusted EBITDA keeps expanding, supporting the existing capital return programme and ongoing regulatory work. The Keensight approach is the swing factor: if it converts near the 80p tender level the share price gravitates towards that mark, and if it lapses the market continues to discount the underlying growth and cash generation. 82p over a 12-month horizon.
Bear Case (16% weight)
Reimbursement cuts in the United States, a negative CMS or private payer decision, or a guideline revision that softens support for routine FeNO testing cause FeNO volumes to stall or contract, exposing the sales concentration risk highlighted in the filings. With no bid to underpin sentiment and a single-product platform, the multiple compresses sharply towards peer medical device averages. 48p over a 12-month horizon.
Key Risks
- FeNO sales concentration: Filings disclose that revenue is heavily concentrated in FeNO asthma testing, leaving the group exposed to a single platform and clinical use case. Estimated probability: 35%. Impact: severe.
- Reimbursement and regulatory headwinds: A cut to US or European reimbursement for FeNO testing, or a negative guideline revision, would directly compress test volumes and consumables revenue. Estimated probability: 25%. Impact: severe.
- Takeover transaction risk: The Keensight approach and 80p tender are central to the case; withdrawal of either without an alternative bid would remove the near-term value crystallisation mechanism. Estimated probability: 30%. Impact: moderate.
- NIOX PRO regulatory timing: Delays or a negative outcome in the NIOX PRO regulatory pathway would push out the next leg of device-led growth and weigh on sentiment. Estimated probability: 25%. Impact: moderate.
- Insider selling: Recent insider share sales, including the 325,273 share disposal by Jonathan Emms, are routine but can be read negatively by a market already sensitive to single-product concentration. Estimated probability: 40%. Impact: low.
- Foreign exchange exposure: Revenue is largely denominated in US dollars and euros while the group reports in sterling, so sterling strength would mechanically reduce reported revenue and margins. Estimated probability: 50%. Impact: low.
Who Should Own It / Avoid It
Ideal for: A UK small-cap healthcare investor with a 12 to 24 month horizon, comfortable with single-product medical device risk and seeking exposure to a cash-generative, debt-free business with a near-term bid-and-tender catalyst overlay. The position is suited to a portfolio that can tolerate event-driven price action around regulatory and takeover news, and that values a 71% gross margin profile combined with a GBP 16.8 million net cash position.
Avoid if: You require diversified revenue across multiple therapeutic areas or platforms, as Niox's exposure is concentrated in FeNO asthma testing. Income investors seeking a fully covered, growing dividend stream should note that the 2025 final dividend remains subject to AGM approval on 21 May 2026, and short-term traders are likely to find the catalyst path too drawn out and binary to trade around reliably.
Recommendation
BUY - 66/100. The tier reflects a constructive view on the combination of the 10-year sensor supply agreement, the GBP 12.5 million tender at 80p, the GBP 16.8 million net cash position and the confirmed Keensight approach, balanced against the disclosed FeNO sales concentration risk and the absence of platform diversification. The call would be upgraded towards a higher conviction tier on conversion of the Keensight approach at or above the tender price, a positive NIOX PRO regulatory outcome, or a sustained acceleration in FeNO test volume growth beyond the 17% recently reported. The call would be downgraded on withdrawal of the Keensight approach without an alternative bid, a US reimbursement cut affecting FeNO, or a material slowdown in clinical consumables growth into the 2027 financial year. At the current price of 63.29p the shares trade above our buy ceiling of 59.33p: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is 89.10p, 41% above the current price of 63.29p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below 59.33p - below this level the upside to the base-case target (82.00p) is at least 2x the downside to the bear case (48.00p), the minimum risk/reward we require before committing new capital.
between 59.33p and 82.00p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above 82.00p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 33%.
if withdrawal of the Keensight takeover approach without an alternative bid, combined with a US reimbursement cut for FeNO testing that drives consumables revenue growth below 5% for two consecutive half-years, regardless of price - the bear target of 48.00p is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 66/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 66 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow drawn from financial press wires, company RNS announcements published via Investegate, investor relations materials hosted on the Niox investor centre, and analyst commentary referenced in third-party reporting. Earnings releases, dividend timetable notices and AGM documentation form the principal source set, with routine market commentary used only for colour rather than as a basis for factual claims.
Primary source types: Regulatory announcements via RNS, company press releases, investor relations materials, earnings results publications, dividend timetable announcements and notice of meeting documentation. Third-party financial press and earnings data aggregators are used only to corroborate items already disclosed in primary filings.
Key sources
- NIOX Group Reports GBP 24 Million H1 Revenue and Launches GBP 12.5 Million Tender Offer
- NIOX Group (NIOX) Investor Relations, Earnings Summary & Outlook
- Niox Group proposes GBP 12.5 million tender offer at 80p per share By Investing.com
- Niox Group proposes GBP 12.5 million tender offer at 80p per share By Investing.com
- NIOX GROUP PLC NIOX Analysis - Stock
- NIOX: NIOX GROUP PLC Stock Price Quote - London - Bloomberg
- NIOX Group (NIOX) H1 2026 Summary | Quartr
- NIOX Group Reports GBP 24 Million H1 Revenue and Launches GBP 12.5 Million Tender Offer
- Niox confirms approach from Keensight, enters formal offer period - Sharecast.com
- NIOX Group Plc: Target Price Consensus and Analysts Recommendations | CIR | GB00BJVD3B28 | MarketScreener
Analysis generated 2026-10-04. Market data as of 2026-11-13.